Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Prospective Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of SZN-8141 in Diabetic Macular Edema

NCT07817121 is registered in ClinicalTrials.gov with Surrozen Operating, Inc. as lead sponsor.

NCT NCT07817121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07817121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Prospective Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of SZN-8141 in Diabetic Macular Edema
Lead sponsor
Surrozen Operating, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
August 31, 2027
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema (dme)